DK2234485T3 - Stabile laquinimod-præparater - Google Patents
Stabile laquinimod-præparaterInfo
- Publication number
- DK2234485T3 DK2234485T3 DK08864658T DK08864658T DK2234485T3 DK 2234485 T3 DK2234485 T3 DK 2234485T3 DK 08864658 T DK08864658 T DK 08864658T DK 08864658 T DK08864658 T DK 08864658T DK 2234485 T3 DK2234485 T3 DK 2234485T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparations
- stable
- stable laquinimod
- laquinimod preparations
- laquinimod
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B25/00—Packaging other articles presenting special problems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mechanical Engineering (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US869807P | 2007-12-20 | 2007-12-20 | |
PCT/US2008/013890 WO2009082471A1 (en) | 2007-12-20 | 2008-12-19 | Stable laquinimod preparations |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2234485T3 true DK2234485T3 (da) | 2014-02-10 |
Family
ID=40788935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08864658T DK2234485T3 (da) | 2007-12-20 | 2008-12-19 | Stabile laquinimod-præparater |
Country Status (12)
Country | Link |
---|---|
US (3) | US8178127B2 (da) |
EP (3) | EP2977049A1 (da) |
DK (1) | DK2234485T3 (da) |
ES (2) | ES2445451T3 (da) |
HK (1) | HK1220126A1 (da) |
HR (1) | HRP20140138T1 (da) |
IL (1) | IL205855A (da) |
PL (2) | PL2234485T3 (da) |
PT (2) | PT2234485E (da) |
RS (1) | RS53199B (da) |
SI (1) | SI2234485T1 (da) |
WO (1) | WO2009082471A1 (da) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
KR101440982B1 (ko) * | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
ZA200810790B (en) | 2006-06-12 | 2010-03-31 | Teva Pharma | Stable laquinimod preparations |
DK2234485T3 (da) | 2007-12-20 | 2014-02-10 | Teva Pharma | Stabile laquinimod-præparater |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
PT2442651E (pt) * | 2009-06-19 | 2015-10-22 | Teva Pharma | Tratamento da esclerose múltipla com laquinimod |
DK2458992T3 (da) * | 2009-07-30 | 2016-02-08 | Teva Pharma | Behandling af crohn's sygdom med laquinimod |
ES2586843T3 (es) * | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
KR20130014523A (ko) * | 2010-03-03 | 2013-02-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 |
PL2542080T3 (pl) * | 2010-03-03 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu |
AU2011223692A1 (en) * | 2010-03-03 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
NZ606589A (en) * | 2010-07-09 | 2015-03-27 | Teva Pharma | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
NZ606587A (en) | 2010-07-09 | 2015-03-27 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
EA201490748A1 (ru) | 2011-10-12 | 2014-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лахинимода и финголимода |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
BR112014020372A8 (pt) * | 2012-02-16 | 2018-01-23 | Teva Pharma | n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
MX2015005632A (es) * | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
WO2014152009A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CA2945978A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
CN114644631A (zh) * | 2020-12-17 | 2022-06-21 | 上海维申医药有限公司 | Kras g12c蛋白突变抑制剂、其制备方法、药物组合物及其应用 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3024257A (en) * | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
DE3437232A1 (de) * | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
US5912349A (en) * | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
PL352882A1 (en) | 1999-06-07 | 2003-09-22 | Altana Pharma Ag | Novel preparation and administration form comprising an acid-labile active compound |
SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
RS51019B (sr) * | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
US6802422B2 (en) * | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
US6706733B2 (en) * | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7560557B2 (en) * | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
JP2006518388A (ja) | 2003-02-20 | 2006-08-10 | ビーピーエスアイ ホールディングス,インコーポレーテッド | 真珠光沢フィルムコーティング剤システム及びそれによりコーティングされた基材 |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US20060188568A1 (en) | 2003-10-30 | 2006-08-24 | Lupin Limited | Stable formulations of ace inhibitors and methods for preparation thereof |
US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
MX2007000536A (es) | 2004-07-16 | 2007-03-07 | Pfizer Prod Inc | Envase farmaceutico para mantener simultaneamente niveles bajos de humedad y oxigeno. |
US8562493B2 (en) | 2005-02-11 | 2013-10-22 | Joseph Haven (Haviv) | Exercise and training apparatus |
KR101440982B1 (ko) * | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
ZA200810790B (en) | 2006-06-12 | 2010-03-31 | Teva Pharma | Stable laquinimod preparations |
DK2234485T3 (da) | 2007-12-20 | 2014-02-10 | Teva Pharma | Stabile laquinimod-præparater |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
PT2442651E (pt) | 2009-06-19 | 2015-10-22 | Teva Pharma | Tratamento da esclerose múltipla com laquinimod |
DK2458992T3 (da) | 2009-07-30 | 2016-02-08 | Teva Pharma | Behandling af crohn's sygdom med laquinimod |
ES2586843T3 (es) | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
KR20130014523A (ko) | 2010-03-03 | 2013-02-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 |
PL2542080T3 (pl) | 2010-03-03 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu |
AU2011223692A1 (en) | 2010-03-03 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
NZ606589A (en) | 2010-07-09 | 2015-03-27 | Teva Pharma | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
NZ606587A (en) | 2010-07-09 | 2015-03-27 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
CA2820586A1 (en) | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
JP2014521658A (ja) | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
CN103781355A (zh) | 2011-07-28 | 2014-05-07 | 泰华制药工业有限公司 | 用拉喹莫德与干扰素-β的组合治疗多发性硬化症 |
EA201490748A1 (ru) | 2011-10-12 | 2014-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лахинимода и финголимода |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
-
2008
- 2008-12-19 DK DK08864658T patent/DK2234485T3/da active
- 2008-12-19 SI SI200831146T patent/SI2234485T1/sl unknown
- 2008-12-19 PT PT08864658T patent/PT2234485E/pt unknown
- 2008-12-19 EP EP15181302.9A patent/EP2977049A1/en not_active Withdrawn
- 2008-12-19 ES ES08864658T patent/ES2445451T3/es active Active
- 2008-12-19 EP EP13187258.2A patent/EP2682120B1/en active Active
- 2008-12-19 ES ES13187258.2T patent/ES2600920T3/es active Active
- 2008-12-19 PL PL08864658T patent/PL2234485T3/pl unknown
- 2008-12-19 WO PCT/US2008/013890 patent/WO2009082471A1/en active Application Filing
- 2008-12-19 EP EP20080864658 patent/EP2234485B1/en active Active
- 2008-12-19 US US12/317,104 patent/US8178127B2/en active Active
- 2008-12-19 PT PT131872582T patent/PT2682120T/pt unknown
- 2008-12-19 PL PL13187258T patent/PL2682120T3/pl unknown
- 2008-12-19 RS RSP20140072 patent/RS53199B/en unknown
-
2010
- 2010-05-20 IL IL205855A patent/IL205855A/en not_active IP Right Cessation
-
2012
- 2012-05-14 US US13/471,175 patent/US8545885B2/en not_active Expired - Fee Related
-
2013
- 2013-09-20 US US14/032,425 patent/US9340307B2/en active Active
-
2014
- 2014-02-13 HR HRP20140138AT patent/HRP20140138T1/hr unknown
-
2016
- 2016-07-13 HK HK16108224.3A patent/HK1220126A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2977049A1 (en) | 2016-01-27 |
US20140024678A1 (en) | 2014-01-23 |
IL205855A0 (en) | 2010-11-30 |
EP2682120B1 (en) | 2016-08-03 |
PT2234485E (pt) | 2014-02-17 |
US8178127B2 (en) | 2012-05-15 |
RS53199B (en) | 2014-06-30 |
HK1220126A1 (zh) | 2017-04-28 |
SI2234485T1 (sl) | 2014-03-31 |
EP2234485A4 (en) | 2011-02-16 |
PT2682120T (pt) | 2016-11-07 |
PL2682120T3 (pl) | 2017-02-28 |
IL205855A (en) | 2017-02-28 |
US20090162432A1 (en) | 2009-06-25 |
ES2445451T3 (es) | 2014-03-03 |
HRP20140138T1 (hr) | 2014-04-11 |
EP2234485A1 (en) | 2010-10-06 |
US9340307B2 (en) | 2016-05-17 |
US8545885B2 (en) | 2013-10-01 |
ES2600920T3 (es) | 2017-02-13 |
PL2234485T3 (pl) | 2014-06-30 |
WO2009082471A1 (en) | 2009-07-02 |
US20120225124A1 (en) | 2012-09-06 |
EP2682120A1 (en) | 2014-01-08 |
EP2234485B1 (en) | 2013-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2234485T3 (da) | Stabile laquinimod-præparater | |
ATE532515T1 (de) | Stabile laquinimod-zubereitungen | |
DK2068886T3 (da) | Lipidholdige præparater | |
DK2164844T3 (da) | Pyrimidinyl-pyridazinonderivater | |
DK2209786T3 (da) | Pyrimidinsubstituerede purinderivater | |
FR2913672B1 (fr) | Joint thermoscellable | |
DK2231614T3 (da) | Quinolinderivativer og anvendelse af disse som fungicider | |
ATE475662T1 (de) | Dihydropyrazolopyrimidinonderivate | |
DK3118221T3 (da) | Proteiner | |
ATE483711T1 (de) | Spiroindolinonderivate | |
ATE512135T1 (de) | Spiroindolinonderivate | |
DK2035394T3 (da) | 2-pyrazincarboxamidderivater | |
BRPI0813836A2 (pt) | Derivados pirazólicos | |
ATE518837T1 (de) | Indazolamidderivate | |
BRPI0807137A2 (pt) | Agentes antiparasitários | |
DK2185142T3 (da) | Antiseptiske midler | |
BRPI0814188A2 (pt) | Formulações | |
DK2152370T3 (da) | Aryletherpyridazinonderivater | |
DK2125048T3 (da) | Præparat | |
DK2086968T3 (da) | 5-hydroxymethyl-oxazolidin-2-on-derivater | |
ATE519760T1 (de) | Isoxazolimidazolderivate | |
ATE467626T1 (de) | Indol-2-yl-piperazin-1-yl-methanon-derivate | |
DK2167469T3 (da) | Sulfonylquinolinderivater | |
FR2907178B1 (fr) | Joint homocinetique | |
FR2897662B1 (fr) | Joint homocinetique |